In clinical trials3,4Evidence: Smaller human trialsGut and digestion

Glepaglutide3

Key takeaway

Glepaglutide is a synthetic, long-acting analogue of glucagon-like peptide-2 (GLP-2), a gut hormone, with a chain of six lysines added at one end.3,4 It is being developed for short bowel syndrome with intestinal failure. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of the two glepaglutide groups reduced the need for parenteral support, nutrition and fluids that bypass the gut, more than placebo; the other did not.4 No FDA approval is reported in the sources reviewed here, and glepaglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,7

Glepaglutide at a glance

What it isA modified GLP-2 analogue with several amino-acid substitutions and a C-terminal hexa-lysine, recorded as glepaglutide in FDA’s substance registry.3
FDA statusNot FDA-approved. None of the sources reviewed here reports an approval of glepaglutide.3,4
Human evidenceOne randomized, double-blind, placebo-controlled Phase 3 trial in 106 patients with short bowel syndrome, published in 2025.4
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is glepaglutide?

Glepaglutide is a synthetic peptide based on human GLP-2, with amino-acid substitutions and six lysines added at the end, according to FDA’s substance registry.3

How is glepaglutide thought to work?

The trial authors describe it as a long-acting GLP-2 analogue developed to improve how the intestine absorbs nutrients and fluid in people with short bowel syndrome.4

What do human studies show?

In the Phase 3 trial, 106 patients with short bowel syndrome who needed parenteral support at least three days a week were randomized to one of two glepaglutide groups or placebo for 24 weeks.4

In one glepaglutide group, weekly parenteral support volume fell more than with placebo, and more patients reached a 20% reduction (65.7% versus 38.9%); five patients were weaned off it entirely. The other group did not differ significantly from placebo.4

ClinicalTrials.gov lists the 2025 trial (NCT03690206) as completed, and a further Phase 3 trial in short bowel syndrome (NCT07197944) as recruiting in its September 29, 2026 record.1,2

What the evidence base contains

  • Controlled human trial A randomized, double-blind, placebo-controlled Phase 3 trial (NCT03690206) in 106 patients with short bowel syndrome and intestinal failure, lasting 24 weeks (2025).4

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is glepaglutide FDA-approved?

None of the sources reviewed here reports an approval of glepaglutide by FDA.3,4

Glepaglutide remains in clinical trials: a Phase 3 registration (NCT07197944) is listed as recruiting in its September 29, 2026 record.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list glepaglutide.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Glepaglutide is not among them.6,7

Timeline

  1. The Phase 3 trial of glepaglutide in 106 patients with short bowel syndrome is published.4

What is still unknown?

Its effects beyond 24 weeks, and why only one of the two glepaglutide groups separated from placebo, which the trial report does not settle.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Glepaglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Glepaglutide are a bounded selection, not every registration or paper about Glepaglutide. For the years before Glepaglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Glepaglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Glepaglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of two glepaglutide groups reduced parenteral support needs. Glepaglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Glepaglutide?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of two glepaglutide groups reduced parenteral support needs. Glepaglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
6
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date September 29, 2026

ClinicalTrials.gov record NCT07197944↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Glepaglutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

9Selected dated records
14Connected citations
6Populated source years2017–2026
2/4Record lanes present

Registered human studies

Trial composition

8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.

PhasesPhase 3 5Phase 1 3
Status at observationCompleted 7Recruiting 1

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesClinical Trial, Phase III 1Journal Article 1Multicenter Study 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
9

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 9 dated records

Research hub

Explore the Glepaglutide evidence record

Open all 9 records →
9Dated records
2Evidence types
9Cited public sources
6Source years

Change ledger

Recently changed for Glepaglutide

Open all 9 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03279302

PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.

PeptideScanner change date
November 16, 2026
Cited source date
December 22, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03690206

PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.

PeptideScanner change date
November 16, 2026
Cited source date
July 17, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03905707

PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.

PeptideScanner change date
November 16, 2026
Cited source date
September 8, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Glepaglutide

Open the full research atlas →
ClinicalTrials.gov8

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07197944Registry update September 29, 2026 · current at observation
  2. NCT03905707Registry update September 8, 2026 · completed at observation
  3. NCT04881825Registry update September 8, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span December 22, 2017 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 9

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07197944↗

    PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03905707↗

    PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04881825↗

    PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  4. Literature metadata

    Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.↗

    PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03690206↗

    PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT04991311↗

    PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT04318743↗

    PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04178447↗

    PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT03279302↗

    PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT07197944 · retained source version 2026-09-29:d17b66ad0d028f8ed1ae307ba724f47af9774ddda187807aa0977fb1675d8eb3 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT03690206 · retained source version 2025-07-17:3e2aff5817a151ae789399cdd4bd45d445559960e7ea0c24fc977217631eb957 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Glepaglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗

    Gastroenterology · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026